PRLD PE Ratio & Valuation,Is PRLD Overvalued

PRLD Relative Valuation

PRLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRLD is overvalued; if below, it's undervalued.

Historical Valuation

Prelude Therapeutics Inc (PRLD) is now in the Fair zone, suggesting that its current forward PS ratio of 4.18 is considered Fairly compared with the five-year average of -4.48. The fair price of Prelude Therapeutics Inc (PRLD) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：2.76

Fair

-2.65

0.00

EV/EBITDA

Prelude Therapeutics Inc. (PRLD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.38. The thresholds are as follows: Strongly Undervalued below -13.95, Undervalued between -13.95 and -8.16, Fairly Valued between 3.41 and -8.16, Overvalued between 3.41 and 9.19, and Strongly Overvalued above 9.19. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-38.39

EV/EBIT

Prelude Therapeutics Inc. (PRLD) has a current EV/EBIT of -38.39. The 5-year average EV/EBIT is -3.33. The thresholds are as follows: Strongly Undervalued below -17.51, Undervalued between -17.51 and -10.42, Fairly Valued between 3.76 and -10.42, Overvalued between 3.76 and 10.85, and Strongly Overvalued above 10.85. The current Forward EV/EBIT of -38.39 falls within the Strongly Undervalued range.

4.18

Prelude Therapeutics Inc. (PRLD) has a current PS of 4.18. The 5-year average PS is 0.14. The thresholds are as follows: Strongly Undervalued below -1.14, Undervalued between -1.14 and -0.50, Fairly Valued between 0.78 and -0.50, Overvalued between 0.78 and 1.43, and Strongly Overvalued above 1.43. The current Forward PS of 4.18 falls within the Strongly Overvalued range.

0.00

P/OCF

Prelude Therapeutics Inc. (PRLD) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.35. The thresholds are as follows: Strongly Undervalued below -23.07, Undervalued between -23.07 and -13.71, Fairly Valued between 5.01 and -13.71, Overvalued between 5.01 and 14.37, and Strongly Overvalued above 14.37. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

899.78

P/FCF

Prelude Therapeutics Inc. (PRLD) has a current P/FCF of 899.78. The 5-year average P/FCF is 27.42. The thresholds are as follows: Strongly Undervalued below -227.98, Undervalued between -227.98 and -100.28, Fairly Valued between 155.12 and -100.28, Overvalued between 155.12 and 282.82, and Strongly Overvalued above 282.82. The current Forward P/FCF of 899.78 falls within the Strongly Overvalued range.

Prelude Therapeutics Inc (PRLD) has a current Price-to-Book (P/B) ratio of 3.55. Compared to its 3-year average P/B ratio of 1.02 , the current P/B ratio is approximately 246.87% higher. Relative to its 5-year average P/B ratio of 2.07, the current P/B ratio is about 71.47% higher. Prelude Therapeutics Inc (PRLD) has a Forward Free Cash Flow (FCF) yield of approximately -44.58%. Compared to its 3-year average FCF yield of -96.81%, the current FCF yield is approximately -53.95% lower. Relative to its 5-year average FCF yield of -64.72% , the current FCF yield is about -31.12% lower.

3.55

P/B

Median3y

1.02

Median5y

2.07

-44.58

FCF Yield

Median3y

-96.81

Median5y

-64.72

Competitors Valuation Multiple

The average P/S ratio for PRLD's competitors is 20.60, providing a benchmark for relative valuation. Prelude Therapeutics Inc Corp (PRLD) exhibits a P/S ratio of 4.18, which is -79.72% above the industry average. Given its robust revenue growth of 116.67%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PRLD increased by 157.27% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.00M to 6.50M.

The secondary factor is the P/E Change, contributed 112.39%to the performance.

Overall, the performance of PRLD in the past 1 year is driven by Revenue Growth. Which is more sustainable.

116.67%

3.00M → 6.50M

Revenue Growth

-71.79%

-1.08K → -303.46

Margin Expansion

112.39%

-0.87 → -1.86

P/E Change

157.27%

1.10 → 2.83

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Prelude Therapeutics Inc (PRLD) currently overvalued or undervalued?

What is Prelude Therapeutics Inc (PRLD) fair value?

PRLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Prelude Therapeutics Inc (PRLD) is between to according to relative valuation methord.

How does PRLD's valuation metrics compare to the industry average?

What is the current P/B ratio for Prelude Therapeutics Inc (PRLD) as of Jan 08 2026?

As of Jan 08 2026, Prelude Therapeutics Inc (PRLD) has a P/B ratio of 3.55. This indicates that the market values PRLD at 3.55 times its book value.

What is the current FCF Yield for Prelude Therapeutics Inc (PRLD) as of Jan 08 2026?

As of Jan 08 2026, Prelude Therapeutics Inc (PRLD) has a FCF Yield of -44.58%. This means that for every dollar of Prelude Therapeutics Inc’s market capitalization, the company generates -44.58 cents in free cash flow.

What is the current Forward P/E ratio for Prelude Therapeutics Inc (PRLD) as of Jan 08 2026?

As of Jan 08 2026, Prelude Therapeutics Inc (PRLD) has a Forward P/E ratio of -2.65. This means the market is willing to pay $-2.65 for every dollar of Prelude Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Prelude Therapeutics Inc (PRLD) as of Jan 08 2026?

As of Jan 08 2026, Prelude Therapeutics Inc (PRLD) has a Forward P/S ratio of 4.18. This means the market is valuing PRLD at $4.18 for every dollar of expected revenue over the next 12 months.

PRLD Valuation